Disclosed herein are methods of treating pulmonary hypertension, including pulmonary arterial hypertension, by administering to a patient in need thereof an effective amount of temozolomide, optionally in conjunction with one or more additional therapeutic agents. Compositions and kits including temozolomide for use in treating pulmonary hypertension, including pulmonary arterial hypertension, are also disclosed.

Perfusion solutions comprising A1AT for the ex vivo perfusion of donor organs are provided to improve donor organ quality and repair damaged donor organs for transplantation. Methods of ex vivo perfusion of donor organs with A1AT-containing perfusion solutions under normothermic temperatures are also provided.

The present invention provides compositions comprising a prostacyclin or prostacyclin analog, or a pharmaceutically acceptable salt thereof for use in preventing or treating cystic fibrosis. The invention also provides the use of a kit comprising a prostacyclin or prostacyclin analog for treating or preventing a condition associated with cystic fibrosis in a subject.

The present invention provides compositions comprising a prostacyclin or prostacyclin analog, or a pharmaceutically acceptable salt thereof for use in preventing or treating cystic fibrosis. The invention also provides the use of a kit comprising a prostacyclin or prostacyclin analog for treating or preventing a condition associated with cystic fibrosis in a subject.

The present disclosure generally relates to treatment of systemic sclerosis with symptomatic Raynaud's Phenomenon by intravenous or subcutaneous administration of iloprost or a pharmaceutically acceptable salt thereof.

The present disclosure generally relates to treatment of systemic sclerosis with symptomatic Raynaud's Phenomenon by intravenous or subcutaneous administration of iloprost or a pharmaceutically acceptable salt thereof.

The present disclosure generally relates to treatment of systemic sclerosis with symptomatic Raynaud's Phenomenon and/or digital ulcers by subcutaneous or intramuscular injection of iloprost or a pharmaceutically acceptable salt or stereoisomer thereof.

The present disclosure generally relates to treatment of systemic sclerosis with symptomatic Raynaud's Phenomenon and/or digital ulcers by subcutaneous or intramuscular injection of iloprost or a pharmaceutically acceptable salt or stereoisomer thereof.

The present disclosure relates to compositions and combinations comprising one or more insulin(s) and one or more vasoactive agent(s), and use thereof for increasing subcutaneous insulin absorption and/or treating diabetes and/or treating or preventing hyperglycemia or complications in a patient in need thereof.

The present disclosure relates to compositions and combinations comprising one or more insulin(s) and one or more vasoactive agent(s), and use thereof for increasing subcutaneous insulin absorption and/or treating diabetes and/or treating or preventing hyperglycemia or complications in a patient in need thereof.